Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, alone and combined with cetuximab or panitumumab, as well as cetuximab plus mFOLFOX chemotherapy, in patients with metastatic colorectal cancer that has a KRAS G12D mutation. This phase 2 study focuses on patients who have either not received prior treatment or have progressed after previous therapies. The goal is to understand how well these treatments work and how safe they are for this specific cancer type. Participants receive one of several treatment regimens VS-7375 alone or combined with cetuximab or panitumumab for patients with second-line or later metastatic colorectal cancer, or VS-7375 combined with cetuximab and mFOLFOX chemotherapy for patients newly diagnosed or with limited prior treatment. The study involves daily oral dosing of VS-7375 and intravenous infusions of the other drugs. Treatments are assigned randomly in a 21 ratio, and participants may cross over between treatments. Throughout the study, participants attend regular visits for evaluations including tumor assessments using RECIST criteria, safety and tolerability monitoring, blood tests for drug levels and tumor markers, and quality of life questionnaires. These assessments occur over periods ranging from 6 months to 2.5 years. The study measures confirmed tumor response rates and monitors for side effects to better understand the potential of these treatments for metastatic colorectal cancer. Participation may last until study completion in late 2028.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, an oral KRAS G12D ONOFF inhibitor, alone and combined with cetuximab in patients with metastatic pancreatic ductal adenocarcinoma PDAC that has the KRAS G12D mutation. This Phase 2, open-label study aims to understand how these treatments work in this specific patient group. The trial is sponsored by Verastem, Inc. and uses a randomized, parallel design.
Actively Recruiting
Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.
Actively Recruiting
Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are studying FMC-376 alone and combined with pembrolizumab in adults with advanced solid tumors that have the KRAS G12C mutation. This clinical trial includes three parts Phase 1A Dose Escalation, Phase 1B Dose Expansion, and Phase 2 Cohort Expansion. It aims to evaluate multiple dose levels and assess safety, pharmacokinetics, and clinical activity in participants with these tumors. Participants will receive FMC-376 orally daily in 21-day cycles, either as monotherapy or combined with pembrolizumab. The study progresses sequentially through dose escalation, dose expansion, and cohort expansion stages to find appropriate dosing and evaluate effects. Those receiving combination therapy must meet additional criteria related to immune health. Throughout the trial, participants will be closely monitored for dose limiting toxicities, adverse events, and overall response over approximately 24 months. Researchers will assess drug levels in blood, response duration, disease control, progression-free and overall survival. The study ensures safety and compliance by evaluating participants health status and organ function regularly.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.
Actively Recruiting
Researchers are evaluating BGB-26808, a HPK1 inhibitor, alone or combined with tislelizumab, an anti-PD-1 antibody, in adults with advanced solid tumors. This phase 1 trial aims to find the recommended dose for BGB-26808 and to assess its safety, tolerability, and preliminary antitumor effects. The study is open-label, nonrandomized in dose escalation, and later includes dose expansion phases.
Actively Recruiting
Researchers are evaluating how well JNJ-101556143 works in people with metastatic androgen pathway modulation-resistant prostate cancer mAPMR, a form of advanced prostate cancer that no longer responds to hormone therapy. This study aims to measure the overall response, including tumor shrinkage or disappearance, after treatment with this investigational drug. The trial is a Phase 2, open-label, multicenter, single-arm study sponsored by Janssen Research & Development, LLC. Participants will receive JNJ-101556143 orally once daily in 28-day treatment cycles. Treatment continues until the disease shows confirmed progression by imaging or clear clinical signs, or if other protocol-defined reasons require stopping. The study evaluates the drugs effects over up to 2 years and 8 months, including response duration, progression-free survival, and time to symptom progression. During the trial, participants will undergo regular assessments including imaging scans, laboratory tests, and measurements of drug levels in the blood to monitor response and safety. Researchers will track adverse events and clinical lab abnormalities throughout. The primary outcome is the overall response rate measured over nearly three years. Participants remain on study until progression or discontinuation criteria are met, with ongoing safety and disease monitoring throughout their participation.
Actively Recruiting
Researchers are studying vobramitamab tavatecan MGC026 to understand its safety, tolerability, how the body processes it, immune response, and early signs of cancer-fighting activity in adults with relapsed or refractory, unresectable, locally advanced, or metastatic solid tumors. This phase 1 trial includes a dose escalation phase and a cohort expansion phase, with an additional module combining MGC026 with pembrolizumab to assess combination therapy effects. Participants receive vobramitamab tavatecan through intravenous infusion every three weeks, with the dose assigned at enrollment. In the combination phase, pembrolizumab is given at 200 mg intravenously every three weeks. Participants may receive up to 35 treatment cycles, provided there are no severe side effects and the cancer does not worsen. The study includes different cohorts and dose levels to explore optimal dosing and combination strategies. During the study, participants are closely monitored for side effects and cancer progression. Blood samples are collected for routine lab work and research, including measuring drug levels and immune responses. Tumor samples may also be collected for research. The primary outcome measures focus on safety and adverse events over up to 135 weeks, while secondary outcomes assess response rates and duration. The study is expected to continue until April 2029, with ongoing evaluations throughout the treatment period.
Actively Recruiting
Researchers are evaluating whether combining pasritamig with docetaxel can extend the time before disease progression, measured by scans or death, compared to docetaxel alone in adults with metastatic castration-resistant prostate cancer. This type of prostate cancer continues to grow despite low male hormone levels. The study is a Phase 3 randomized trial designed to compare these treatments in this patient population. Participants are assigned to one of two groups. One group receives pasritamig together with docetaxel until disease progression or treatment end. The other group receives docetaxel plus prednisone or prednisolone as background medication. The study uses imaging scans and other criteria to monitor disease progression. The study treatment continues until certain protocol-defined endpoints are met. During the study, participants undergo various scans including CT, MRI, and bone scans to assess disease status. Researchers monitor progression-free survival and other outcomes such as overall survival, symptom progression, and quality of life using questionnaires. Safety is tracked by recording adverse events, lab abnormalities, and treatment side effects. Follow-up lasts up to about four and a half years, allowing comprehensive evaluation of treatment impact and safety.
1-10 of 25
1